The NF-κB inflammatory pathway plays a major role in cancer development and clinical progression. Activation of NF-κB signaling is promoted by NFKB1 and inhibited by NFKBIA. The present study aimed to determine the relevance of NFKB1 rs4648068 and NFKBIA rs2233406 genetic variants for non-medullary thyroid cancer (NMTC) susceptibility, progression and clinical outcome. This case-control and cohort study consists of a Romanian discovery cohort (157 patients and 258 controls) and a Dutch validation cohort (138 patients and 188 controls). In addition, patient cohorts were analyzed further for the association of genetic variants with clinical parameters. Functional studies were performed on human peripheral blood mononuclear cells. No associations were observed between the studied genetic variants and TC susceptibility. Although no statistically significant associations with clinical parameters were observed for NFKB1 rs4648068, the heterozygous genotype of NFKBIA rs2233406 was correlated with decreased radioactive iodide sensitivity requiring higher cumulative dosages to achieve clinical response. These findings were discovered in the Romanian cohort (P < 0.001) and confirmed in the Dutch cohort (P = 0.01). Functional studies revealed that this NFKBIA rs2233406 genotype was associated with elevated TLR4-mediated IL-1β production. In conclusion, genetic variation in NFKBIA, an inhibitor of NF-κB signaling, is associated with clinical response to RAI therapy and with increased production of the pro-inflammatory cytokine IL-1β, providing a potential mechanism for the observed clinical associations. These data suggest that NF-κB signaling is involved in NMTC pathogenesis and that the inflammatory tumor microenvironment could contribute to RAI resistance.
Introduction
Non-medullary thyroid cancer (NMTC), including papillary (PTC) and follicular (FTC) histological subtypes, is the most common endocrine cancer with rising incidence (Jemal et al. 2011 , Morris et al. 2013 , Pellegriti et al. 2013 . Although the majority of patients with NMTC have a good prognosis, patients with advanced NMTC are rarely cured, 24:7 mainly because their tumors lose the ability to accumulate radioactive iodide (RAI). This is due to loss of sodium iodide symporter (NIS) expression (Riesco-Eizaguirre et al. 2006 , Durante et al. 2007 , Mian et al. 2008 . Inhibition of inflammatory pathways, including signaling through nuclear factor κB (NF-κB), has been proposed as a potential therapeutic target for patients with RAI refractory disease (Pacifico & Leonardi 2010 , Li et al. 2013 .
NF-κB proteins represent a family of transcription factors including five members: RelA (p65), RelB, c-Rel, NF-κB1 (p50) and NF-κB2 (p52). After protein synthesis, homo-or heterodimers of these proteins are assembled in the cytoplasm. In the inactive state, NF-κB protein dimers are conjugated with IκBα (encoded by the NFKBIA gene) to prevent nuclear translocation of NF-κB. However, upon the encounter of a wide variety of extracellular or intracellular stimuli, nuclear translocation and transcriptional activity of NF-κB is enabled by proteasomal degradation of IκBα (Pacifico & Leonardi 2010 , Li et al. 2013 .
Besides its function in inflammatory pathways, the NF-κB signaling cascade is one of the most important intracellular pathways in cancer development and progression by influencing cell survival, carcinogenesis, proliferation and anticancer drug resistance. Previous studies have shown that NF-κB is upregulated in many different cancer types and is associated with poor outcome (Hoesel & Schmid 2013 , Xia et al. 2014 . In NMTC, it has also been reported that NF-κB signaling can play an important role in carcinogenesis through its contributions to inhibition of apoptosis (Bravo et al. 2003 , Pacifico et al. 2004 , Starenki et al. 2004 , induction of carcinogenesis by chronic inflammation (Kato et al. 2006 , Pacifico & Leonardi 2010 and promotion of tumor invasiveness (Palona et al. 2006 , Bauerle et al. 2010 , Cras et al. 2012 . Furthermore, NF-κB signaling has been shown to intertwine with other pathways promoting NMTC pathogenesis, including BRAF, JNK, PI3K, RET and TGFβ (Namba et al. 2007 , Bommarito et al. 2011 , Neely et al. 2011 .
Besides its effects on tumorigenesis and tumor progression, NF-κB is also an important factor that can contribute to resistance to anticancer therapies. Studies into NMTC have shown that active NF-κB may be associated with decreased therapeutic efficacy of RAI, the standard adjuvant therapy administered to patients after surgery (Meng et al. 2012a,b) . However, the underlying mechanism of this effect has not been completely elucidated.
Gene polymorphisms of the NF-κB pathway have been related to the susceptibility of various cancer types including multiple myeloma (Parker et al. 2002) , nonHodgkin lymphoma (Giachelia et al. 2012) , melanoma (Bu et al. 2007) , colorectal cancer (Seufert et al. 2013) and lung cancer (Shiels et al. 2012) and have been linked to therapeutic response (Bu et al. 2007 , Giachelia et al. 2012 ) and patient survival (Ungerback et al. 2012) . This association could be racial-specific (Nian et al. 2014) , at least for some cancer subtypes (Lehnerdt et al. 2008 , Zhou et al. 2009 ). In Table 1 , a complete list of all genetic associations between polymorphisms in NF-κB-related genes with endocrine-related cancers is provided, including thyroid cancer, breast cancer, ovarian cancer and prostate cancer. This list indicates that no studies have been performed into the role of NF-κB polymorphisms in relation to therapy response.
Although previous studies have established an important role for NF-κB in cancer, and in NMTC in particular, the clinical relevance of genetic variation in genes encoding components of the NF-κB pathway for NMTC pathogenesis and clinical outcome has been hardly investigated so far. Only one previous study has examined Thyroid cancer rs28362491 Susceptibility Breast cancer (Wang et al. 2014 , Eskandari-Nasab et al. 2016 rs28362491, rs2233406 Susceptibility (Jamshidi et al. 2015) rs5996080, rs7973914, rs17243893, rs57890595
Survival (Murray et al. 2013) rs230532, rs3774932 Clinical outcome Ovarian cancer (Fan et al. 2011 , Huo et al. 2013 , Chen et al. 2015a , Lu et al. 2016 rs230528, rs230521, rs4648068, rs3774964, rs3774968, rs28362491
Susceptibility
Prostate cancer (Zhang et al. 2009 , Kopp et al. 2013 , Cui et al. 2015 , Han et al. 2015 rs28362491, rs2233406, rs3138053, rs28362491
Susceptibility the rs28362491 insertion/deletion polymorphism in NFKB1 and has identified this polymorphism as a susceptibility factor for PTC . We hypothesize that NF-κB-related genetic variants could represent important risk factors in development or clinical progression of NMTC and could improve our understanding of the mechanisms responsible for the effects of NF-κB on RAI responsiveness. In the present study, single-nucleotide polymorphisms in NFKB1 (rs4648068) and NFKBIA (rs2233406) genes were evaluated for their role in susceptibility, progression and clinical outcome of NMTC patients. These genes and genetic variants were selected based on population frequency and previously published associations with human diseases and/or known functional effects on protein function or gene expression (Bu et al. 2007 , Lu et al. 2012 , Ali et al. 2013 , Tan et al. 2013 , Hua et al. 2014 , Chen et al. 2015a . Further, functional consequences of genetic variation in NF-κB genes were investigated for the production of pro-inflammatory cytokines that are important factors in the tumor microenvironment and could therefore be involved in both tumorigenesis and response to therapy.
Study subjects and methods

Study subjects
Patients with histologically confirmed NMTC who visited the Endocrinology Department at the Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca or the Oncology Institute Cluj-Napoca, Romania or the outpatient clinic at the Division of Endocrinology of the Department of Medicine, Radboud University Medical Center, Nijmegen, the Netherlands, were asked to provide blood for genetic testing. In total, 157 NMTC Romanian patients (collected between 2014 and 2015, discovery cohort) and 138 consecutive NMTC Dutch patients (collected between 2009 and 2010, validation cohort) were enrolled in the study. Total thyroidectomy was performed in all cases in addition to modified radical lymph node neck dissections in patients with confirmed nodal metastases. RAI ( 131 I) ablation of residual thyroid tissue was performed 4-6 weeks after surgery. After this initial treatment, patients were considered in remission if they had a TSH-stimulated thyroglobulin (Tg) < 1 pM/l in the absence of anti-Tg antibodies and no evidence of loco-regional disease or distant metastasis on the whole body iodine scans (WBS) and/or neck ultrasonographic examinations at 6-9 months after the ablation. If this was not the case, patients were repeatedly treated with RAI to reach remission, if indicated. In fact, all patients who were not cured at the last follow-up had received more than 200 mCi RAI during the course of their disease. Tumor recurrence was defined as new evidence of loco-regional disease or distant metastasis after successful primary therapy. Current disease status was defined as remission (or cured) in case of undetectable Tg in the absence of anti-Tg antibodies and no evidence of loco-regional disease or distant metastases at the last follow-up visit. Persistent or recurrent disease was defined as detectable Tg and/or evidence of loco-regional disease or distant metastases. For all definitions based on Tg levels, the absence of anti-Tg antibodies was required. Histological, clinical and follow-up data were retrieved from the patients' medical records and are shown in Table 2 . In the Romanian cohort, significantly more female patients were included as compared to the Dutch cohort, and T-stage, M-stage and cumulative RAI dose distribution were also significantly different between the cohorts. In addition, 258 Romanian and 188 Dutch healthy, genetically unrelated individuals, having no evidence of NMTC or other malignancies, were recruited as population-based control subjects from either the Dutch (Nijmegen area) or the Romanian population (Cluj-Napoca area) by local advertising. These control cohorts are healthy population-based groups not knowingly been affected by any type of malignancy or other type of disease that was selected to fit the patient cohorts with respect to age and gender. All control subjects are of adult age ranging from 18 to 65 years. Control subjects were not individually matched with patients; however, a similar distribution of age and gender in all cohorts was reached by selection of appropriate control subjects. Furthermore, gender has a minor influence on the genetic susceptibility analysis, since genetic variants in NFκB genes are located on autosomal chromosomes 4 or 14, which are therefore inherited irrespective of gender.
Ethics statement
The study has been performed in accordance with the Declaration of Helsinki, and approval was obtained from the Ethics Committees of Iuliu Hațieganu University of Medicine and Pharmacy Cluj-Napoca, Romania and Radboud University Medical Center, Nijmegen, the Netherlands. Informed consent has been obtained from each patient or subject after full explanation of the purpose and nature of all procedures used.
Genotyping
Single-nucleotide polymorphisms (SNPs) were selected based on population frequency and previously published associations with human diseases and/or known functional effects on protein function or gene expression , Chen et al. 2015a . After obtaining informed consent, blood was drawn from the cubital vein of participants into EDTA collection tubes and subjected to DNA extraction using the GeneJET Whole Blood Genomic DNA Purification Mini Kit (Fermentas, Thermo Fisher Scientific, USA) according to the manufacturer's instructions. Until further analysis, DNA samples were stored at −20°C. TaqMan SNP Genotyping assays (Life Technologies, Carlsbad, CA, USA) designed with two specific probes, and primers for each variant were utilized for genotyping the SNPs in NFKB1 (rs4648068, C_11345289_10) and NFKBIA (rs2233406, C_73867_10). Ten nanograms of genomic DNA were amplified by quantitative polymerase chain reaction (qPCR) in a 7300 Real-Time PCR System (Life Technologies, Carlsbad, CA, USA), under standard conditions. The real-time PCR included an initial denaturation step at 95°C for 10 min, followed by 40 cycles at 95°C for 15 s and then at 60°C for 1 min. Quality control was performed by duplicating samples within and across plates and by the incorporation of positive and negative control samples.
Cytokine production by peripheral blood mononuclear cells (PBMC) and NMTC cell lines
For PBMC isolation, venous blood was drawn from the cubital vein of healthy volunteers into 10 mL EDTA tubes (Monoject). The mononuclear cell fraction was obtained by density centrifugation of blood diluted 1:1 in pyrogenfree saline over Ficoll-Paque (Pharmacia Biotech, PA, USA). Cells were washed twice in saline and suspended in culture medium (RPMI, Invitrogen, CA, USA) supplemented with gentamicin 10 µg/mL, l-glutamine 10 mM and pyruvate 10 mM. NMTC cell lines BC-PAP and FTC133 were obtained from the sources previously described and were authenticated by short tandem repeat profiling (Schweppe et al. 2008) . BC-PAP and FTC133 cell lines were cultured in RPMI or DMEM culture medium, respectively (Invitrogen, CA, USA), both supplemented with gentamicin 10 µg/mL, l-glutamine 10 mM and pyruvate 10 mM. Cells were counted in a Coulter counter (Coulter Electronics), and the number was adjusted to 5 × 10 6 cells/mL. A total of 5 × 10 5 cells in a 100 µL volume was added to 96-well plates (Greiner) and incubated with either 100 µL of culture medium (negative control) or with E.coli lipopolysaccharide (LPS, 10 ng/mL, Sigma, MO, USA). Cytokine measurements of IL-1β, TNFα and IL-6 were performed in the supernatants after 4 and/or 24 h incubation, using a commercial ELISA kit (R&D Systems, MN, USA).
Statistical analysis
Genotype and allele frequencies were calculated, and the Hardy-Weinberg equilibrium was assessed using a goodness-of-fit χ 2 -test for biallelic markers. The odds ratios (ORs) and 95% confidence intervals (95% CI) of the association between genotype frequencies and NMTC susceptibility in addition to clinicopathological characteristics and treatment outcomes were analyzed using binary logistic regression models. In addition, χ 2 analysis and Fisher's exact tests were applied to determine whether histology, TNM staging, cumulative RAI dose (subdivided as 0-100 mCi (0-3.8 GBq), 101-200 mCi (3.8-7.4 GBq) or >7.4 GBq (>200 mCi)) and disease status 
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after thyroidectomy plus radioablation were associated with the genotype of the analyzed genes. All statistical analyses were carried out with SPSS v22.0 for statistical computing. Differences in cytokine production capacity between groups were analyzed using the Kruskal-Wallis test. Overall, statistical tests were two-sided, and a P value below 0.05 was considered statistically significant.
Results
NF-κB pathway SNPs and susceptibility to non-medullary thyroid cancer
To assess the effects of genetic variation in NF-κB genes on susceptibility to NMTC, two SNPs were selected based on previously published associations with human diseases and/or known functional effects on protein function or gene expression: the intronic SNP rs4648068 in NFKB1 and the 5ʹ UTR SNP rs2233406 (also known as -839A/G) in NFKBIA. The genotypes corresponding to these SNPs were determined in the Romanian discovery cohort (157 patients, 258 healthy controls) and in the Dutch validation cohort (138 patients, 188 healthy controls). Table 2 summarizes the main clinical and demographical characteristics of the selected Romanian and Dutch NMTC patients. Of note, the distribution of age and sex was not significantly different between patient and control groups, since the controls were selected to fit the patient cohorts (data not shown). The distribution of NFKB1 and NFKBIA genotypes among the Romanian and Dutch cohorts is presented in Tables 3 and 4 , respectively. The results indicate that no significant associations were observed between the selected SNPs in either NFKB1 or NFKBIA and susceptibility to develop NMTC, irrespective 
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of the chosen genetic association model (i.e. dominant, recessive or gene dose-dependent model). Also, no statistically significant associations were observed after stratifying for gender, as was reported previously for the NFKBIA rs2233406 polymorphism in colorectal cancer patients (Tan et al. 2013 ) (data not shown). Of note, genotype frequencies in both NMTC patients and controls study populations were in accordance with that expected under the Hardy-Weinberg equilibrium (Tables 3 and 4) .
NF-κB pathway SNPs and clinical outcome of NMTC
Within the NMTC study populations recruited in Romania and the Netherlands, the impact of NFKB1 or NFKBIA genotypes on the clinical postoperative treatment response and outcome of NMTC patients was investigated. With regard to the NFKB1 rs4648068 SNP, no statistically significant differences were found in any of the patient cohorts for any of the selected clinical parameters. Interestingly, however, the NFKBIA rs2233406 SNP was significantly associated with the required cumulative RAI dose to reach remission, reaching statistical significance in both the Romanian and Dutch cohorts. These genetic associations indicate that in both cohorts especially the heterozygous GA genotype is overrepresented in the patient group receiving a relatively high cumulative RAI dose above 200 mCi, whereas in patients with either homozygous genotype (AA or GG), a lower RAI dose was more likely to be sufficient to achieve clinical response. Nevertheless, between the NFKBIA rs2233406 genotype groups, no differences were observed concerning the rate of disease persistence or disease recurrence as measure of patient outcome, neither in the Romanian nor in the Dutch patient cohorts ( that received a cumulative RAI dose of ≥200 mCi by repeated treatments eventually reached remission. Within these subgroups, no significant associations with either NFKB1 or NFKBIA genotype were observed. Furthermore, after genotype stratification, no statistically significant differences were observed between Dutch and Romanian patients for any of the included clinical parameters (data not shown). Since for some statistical analyses the Fisher's exact test is also appropriate, differences in statistical output of Fisher's exact tests were assessed in relation to chi-square tests. Importantly, no important differences in statistical significance were observed between the results of the two tests.
Functional consequences of NF-κB SNPs for LPS-induced pro-inflammatory cytokine production by peripheral blood mononuclear cells
NF-κB is a well-established transcription factor for the expression of proteins involved in inflammatory pathways including pro-inflammatory cytokines as important mediators of inflammatory signals. In order to study the functional effects of NFKB1 rs4648068 and NFKBIA rs2233406 polymorphisms for the inflammatory response, PBMCs obtained from healthy volunteers with different NFKB1/NFKBIA genotypes were stimulated with lipopolysaccharide (LPS) for 24 h and IL-1β, TNFα and IL-6 production was measured in the supernatants. No differences were observed between different NFKB1 rs4648068 genotypes for production of LPS-induced IL-1β, TNFα or IL-6 (Fig. 1A) . In contrast, after stratifying for the NFKBIA rs2233406 genotype, statistically significant differences were obtained for the production of LPSinduced IL-1β, which was specifically higher in PBMCs from GA heterozygous individuals as compared to cells with either AA or GG homozygous genotypes. Similar trends were observed for the production of TNFα and IL-6, although no statistically significant differences were reached (Fig. 1B) . In the unstimulated conditions, cytokine concentrations were below detection limit (data not shown).
IL-1β production by NMTC cell lines
To assess whether NTMC cell lines are responsive to LPS, NMTC cell lines BC-PAP and FTC133 were cultured in the presence of LPS for 4 and 24 h. Measurement of the supernatants revealed detectable production of IL-1β by LPS-stimulated cells, whereas IL-1β was not measurable in the negative control conditions (Fig. 2) .
Discussion
The present study was performed to investigate whether frequent genetic variants in human genes encoding NF-κB pathway components are associated with NMTC susceptibility, severity and/or clinical outcome in a Romanian discovery cohort and a Dutch validation cohort. Interestingly, one of the selected genetic variants, the NFKBIA rs2233406 single-nucleotide polymorphism, was significantly associated with the clinical response of NMTC patients to RAI therapy, which was discovered in the Romanian cohort and confirmed in the Dutch cohort. In both cohorts, the heterozygous GA genotype conferred relative resistance to RAI therapy, whereas carriers of the AA and GG homozygous genotypes exhibited a better clinical response to RAI treatment. In the Dutch validation cohort, a statistically less significant association of the NFKBIA rs2233406 genotype with cumulative RAI dose was observed as compared to the Romanian discovery cohort. These differences in significance between the Dutch and Romanian cohorts could originate from the observed differences between the Dutch and Romanian patient cohorts listed in Table 2 with respect to distribution of gender, T-stage, M-stage and cumulative RAI dose. Nevertheless, we are confident that this represents a true genetic association, since the same NFKBIA rs2233406 GA genotype is associated with decreased RAI responsiveness in both cohorts. This is further corroborated by functional data demonstrating aberrant cytokine production in the presence of the NFKBIA GA genotype. In contrast, no significant associations were observed between NF-κB genetic variants and susceptibility to develop NMTC. Furthermore, for the other selected polymorphism, NFKB1 rs4648068, no associations were observed with either susceptibility for NMTC, severity of the disease or clinical outcome. Also, after genotype stratification, no statistically significant differences were observed between Dutch and Romanian patients for any of the included parameters. Functional studies into the biological effects of the NFKBIA rs2233406 polymorphism revealed that specifically the GA heterozygous genotype, which was significantly associated with a worse clinical response to RAI treatment, was also associated with an increased production of IL-1β elicited by PBMCs stimulated with LPS, a well-known ligand of Toll-like receptor 4 (TLR4). This is in accordance with a previous study demonstrating that the NFKBIA rs2233406 heterozygous GA genotype is associated with decreased NFKBIA expression and IkBα protein levels, allowing for elevated production of IL-1β (Ali et al. 2013) . No differences in cytokine production were observed between LPS-stimulated PBMCs stratified for the NFKB1 rs4648068 genotype. These functional data are in line with the genetic association data and suggest a potential role for IL-1β production contributing to RAI therapy resistance. In fact, it has been demonstrated previously that IL-1β signaling negatively influences expression of NIS, a critical prerequisite for RAI accumulation in malignant thyroid follicular cells (Yamashita et al. 1989 , Ohta et al. 1996 , Spitzweg et al. 1999 . One might hypothesize that increased production of LPS-induced IL-1β, observed in PBMCs bearing the NFKBIA rs2233406 GA heterozygous genotype, could therefore impair clinical responses to RAI by downregulating NIS. Notably, also thyrocytes are known to express TLR4 and are capable of responding to LPS (Nicola et al. 2009 ). Consequently, autocrine and paracrine IL-1β signaling could also be evoked by malignant thyroid follicular cells themselves in response to certain TLR4 agonists, being either LPS or, perhaps more likely, danger-associated molecular patterns that activate TLR4 signaling such as HMGB1, which is present in high amounts in the tumor microenvironment (Yu et al. 2006) . In this respect, in the present study, we could demonstrate that malignant thyroid follicular cells BC-PAP and FTC133 are capable of recognizing LPS and of eliciting IL-1β production. Moreover, within the tumor microenvironment, tumor-associated macrophages 24:7 (TAMs) might also be an important source of IL-1β production induced by TLR4 signaling. These TAMs have been found to be abundantly present in advanced NMTC and are associated with a poor prognosis (Ryder et al. 2008) . The rs2233406 polymorphism in NFKBIA, an inhibitor of NF-κB signaling, is located in the promoter region and could therefore influence the regulation of NFKBIA expression. The observation that the GA heterozygous genotype of NFKBIA rs2233406 leads to differential regulation of IL-1β production as compared to the AA and GG homozygous genotypes suggests that both homozygous genotypes exhibit similar consequences as a result of different effects on NFKBIA expression: either too high or too low expression. Importantly, the direct functional consequences of this polymorphism on NFKBIA expression and function remain to be investigated.
These novel data indicate a potential role of NF-κB signaling in the pathogenesis of NMTC and suggest that the inflammatory tumor microenvironment could contribute to RAI resistance. These results warrant further investigations into the role of the tumor microenvironment in the regulation of NIS expression and in the progression of NMTC in order to identify potential therapeutic targets that may enhance RAI sensitivity in patients with advanced therapy refractory disease.
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